MetaCap

Oric Pharmaceuticals (ORIC) vs Pharming Group N.V. (PHAR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pharming Group N.V. (PHAR) has outperformed Oric Pharmaceuticals (ORIC) over the past year, losing 29.0% versus a loss of 36.7%. Over five years, PHAR leads with a +39.0% price change compared with -48.6% for ORIC. Pharming Group N.V. is the larger company by market cap ($816.8 million vs $764.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ORIC-36.66%PHAR-29.03%
+34%-7%-48%
Nov 21, 20251 yearNov 20, 2026
ORIC-55.39%PHAR+33.87%
+149%+26%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ORIC versus PHAR key metrics
MetricORICPHAR
Share price$7.36$11.54
Market cap$764.94M$816.78M
1-day change-4.42%-5.10%
YTD return-10.02%-34.69%
1-year return-36.66%-29.03%
5-year return-48.64%+39.04%
P/E ratio (TTM)—36.06
Forward P/E—64.11
EPS (TTM)$-1.44$0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$376.13M
Revenue growth (YoY)—+26.56%
Net income (latest FY)$-129.47M$2.85M
Gross margin—87.90%
Operating margin—6.87%
Net margin—0.76%
52-week high$14.68$21.34
52-week low$7.23$9.11
Distance from 52-week high-49.86%-45.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+194.97%+209.36%
Average volume1.59M21.33K
Shares outstanding103.93M70.78M
Employees111407
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Oric Pharmaceuticals

ORIC stock →

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees

About Pharming Group N.V.

PHAR stock →

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees

ORIC vs PHAR FAQ

Which is bigger, Oric Pharmaceuticals or Pharming Group N.V.?

Pharming Group N.V. (PHAR) is larger, with a market capitalization of $816.78M compared with $764.94M for Oric Pharmaceuticals (ORIC).

Which stock has performed better over the past year, ORIC or PHAR?

PHAR returned -29.03% over the past 12 months, compared with -36.66% for ORIC (price return, excluding dividends). Past performance does not predict future results.

Are Oric Pharmaceuticals and Pharming Group N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons